Gastroesophageal Cancers — Proceedings from a Symposium Held in Conjunction with the American Oncology Network

Oncology Today with Dr Neil Love · Sep 28, 2026 · 50:22

Listen in the Podli app 🎧

Follow your favourite podcasts, listen offline and in the car with CarPlay and Android Auto, and always pick up where you left off. Free to try.

Featuring perspectives from Dr Samuel J Klempner and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics:

Introduction (0:00)
First-Line Treatment of Metastatic Gastroesophageal Cancer (1:48)
Management of HER2-Positive Gastroesophageal Cancer (25:11)
Neoadjuvant Therapy for Gastroesophageal Cancer (45:13)

Note to listeners: Subsequent to the recording of this symposium, the FDA approved zanidatamab in combination with chemotherapy with and without tislelizumab for HER2-positive gastric, gastroesophageal junction, or esophageal adenocarcinoma based on results from the Phase III HERIZON-GEA-01 trial.

CME information and select publications